Organization | National Heart Institute, Egypt

National Heart Institute, Egypt Report issue

Government Phase 3

Organization Overview

First Clinical Trial

2014

NCT02728518

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

National Heart Institute, Egypt

Active Ingredients

Drugs in Phase 3 Trials (8)

canagliflozin (invokana) (1 trial)

carvedilol (coreg) (1 trial)

dapagliflozin (farxiga) (2 trials)

empagliflozin (jardiance) (1 trial)

glucose (1 trial)

ivabradine (corlanor) (1 trial)

ramipril (altace) (1 trial)

spironolactone (aldactone) (1 trial)

Drugs in Other Trials (1)

amikacin (Amikin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Non-ST Elevated Myocardial Infarction (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 9